Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 11/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539091 | 0.88 | HTR4 (0.61) | HTR4HTR3AGAAKCNH2 | |
| SCHEMBL3544464 | 0.88 | HTR4 (0.61) | HTR4HTR3AGAAKCNH2 | |
| SCHEMBL3540287 | 0.85 | USP2 (0.53) | HTR4HTR3AGAA | |
| SCHEMBL3550487 | 0.84 | GAA (0.55) | HTR4HTR3AGAA | |
| SCHEMBL1780880 | 0.82 | MEN1 (0.55) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| SCHEMBL1780879 | 0.82 | MEN1 (0.55) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| SCHEMBL3543720 | 0.82 | MEN1 (0.55) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| SCHEMBL3543722 | 0.82 | MEN1 (0.55) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| SCHEMBL1781337 | 0.80 | ACKR3 (0.49) | — | |
| SCHEMBL3540628 | 0.78 | USP30 (0.47) | CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | HTR4 3043/4885HTR3A 2998/4885GAA 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.